Investcorp, Bahrain-based leading global alternative investment firm, has invested $17.5 million in V-Ensure Pharma Technologies, an India-based private limited company, marking its first investment in the pharmaceutical sector of the South Asian country.
The round was led by Investcorp along with participation from an Asia-based private investment firm, Tanas Capital. The investment will fund V-Ensure’s objective of pursuing growth opportunities across North America, Europe and other global markets for the development and launch of its products.
The investment will also strengthen Investcorp’s commitment to fund market-leading business services, information technology and healthcare businesses in India and accelerate their expansion and competitive positioning globally.
Founded in 2010, V-Ensure is a leading developer of specialty pharmaceutical formulations focused on complex generics for regulated markets. The company’s core competence lies in the development of complex molecules for regulated markets without infringing on any existing patents. V-Ensure has developed solid oral, liquid oral and injectable products for more than 45 clients across Europe, North America, China, Australia and Brazil.
Gaurav Sharma Partner & Head India Private Equity Investcorp India
“As our first pharmaceutical deal in India, we are confident that healthcare globally will continue to be center stage for the future. V-Ensure is a renowned name among India-based pharmaceutical research organizations which aim to tap global markets with its own products. Investcorp’s global presence and knowledge will potentially help V-Ensure as they look to establish their presence directly in the US market. We look forward to this partnership and supporting the company in scaling its operations, both in India and globally, drawing upon our global mid-market expertise.”
Mr. Satyanarayana Vemula, CEO of V-Ensure stated, “We are delighted to partner with Investcorp as we expand our business from a Contract Research Organization to a fully integrated specialty pharmaceutical company. We will continue to deliver patient-centric solutions through our proprietary technology and competence in developing complex generics for regulated markets.”
Investcorp has been active in the mid-market private equity space in India since 2019, investing across the healthcare, businesses services, financial services, consumer & retail, and technology sectors.
Earlier this year, the company issued its 2021 Responsible Business Report which outlines its approach to responsible investing and progress against its Environmental, Social, and Governance (EGS) commitments. The firm’s capital deployment in India is an integral part of its ESG strategy.
Investcorp’s investments over the last four years include Nephroplus, Wingreens, Intergrow Brands, Bewakoof.com, FreshToHome, Zolostays, InCred, Citykart, ASG Eye Hospital, Unilog, Xpressbees, and Safari Industries.
